GOP Drug Shortage Strategy Pushes FDA Reform, Reimbursement Over Notification
Executive Summary
House hearing includes arguments that regulatory delays thwart the market’s response to shortage price signals, suggesting reforms could be included in user fee legislation along with the popular early warning requirement.
You may also be interested in...
Drug Shortage Scrutiny: GAO Plans Study Of FDA’s Expedited Applications
Government watchdog wants to look at how the agency expedites applications that could help alleviate a shortage, but cautions that process alone cannot reduce shortages.
FDA Wants Compounding Authority Clarified, Congress Not So Sure It’s Necessary
Commissioner Hamburg asks for more power over non-traditional compounding to better regulate companies like the New England Compounding Center, but several House members say it looks like the agency already has the authority it needs.
Compounding Hearings Are First Step In Creating Active Legislative Ingredients
Congress will explore causes and potential policy solutions to the meningitis outbreak at the New England Compounding Center in back-to-back hearings, but any legislation increasing FDA regulatory authority faces a long road.